ALUNBRIG Market Summary

Key Factors Driving ALUNBRIG Growth

1. Superior first-line efficacy versus crizotinib: The Phase III ALTA-1L trial established ALUNBRIG as a strong first-line ALK inhibitor. At final analysis, median progression-free survival (PFS) was 24.0 months with brigatinib versus 11.1 months with crizotinib, corresponding to a 52% reduction in the risk of progression or death (HR 0.48). Three-year PFS was 43% versus 19%, respectively. This durable benefit supports continued uptake in newly diagnosed ALK-positive metastatic NSCLC.

2. Strong CNS penetration and intracranial efficacy: Brain metastases are common in ALK-positive NSCLC, making CNS activity an important differentiator. In ALTA-1L, the confirmed intracranial response rate among patients with measurable brain lesions was 78% with brigatinib versus 29% with crizotinib. The final analysis also suggested an overall-survival benefit among patients with baseline brain metastases (HR 0.43). This makes ALUNBRIG particularly attractive for patients with CNS involvement.

3. Long-term durability of treatment benefit: Updated long-term data demonstrate that ALUNBRIG's activity is not limited to short-term tumor responses. In the previously crizotinib-treated ALTA population, the 180-mg regimen achieved a median PFS of 16.7 months and median overall survival of 40.6 months; median intracranial PFS among patients with brain metastases was 18.4 months. Such durable disease control can support longer treatment duration and sustained product utilization.

4. Expansion into newly diagnosed patients materially enlarged the addressable market: ALUNBRIG initially received US accelerated approval in 2017 for metastatic ALK-positive NSCLC after crizotinib progression/intolerance. In May 2020, the FDA expanded its indication to adult patients with ALK-positive metastatic NSCLC detected by an FDA-approved test, enabling first-line use. Takeda subsequently obtained first-/second-line approval in Japan in January 2021 and approval in China in March 2022. The first-line expansion is particularly important because it allows ALUNBRIG to compete for patients before exposure to another ALK TKI.

5. Growing geographic penetration, particularly in China and emerging markets: Takeda has specifically reported strong demand across regions as an important driver of ALUNBRIG's commercial performance. In FY2023, ALUNBRIG revenue reached JPY 28.5 billion, an increase of 38.8% year over year at actual exchange rates and 35.3% at constant exchange rates, with Takeda citing strong demand across all regions. Earlier, Takeda also reported 39% CER growth driven by Europe, Growth & Emerging Markets and China.

ALUNBRIG Recent Developments

• A new China focused real world treatment duration study initiated in March 2026.
• Ongoing post marketing safety surveillance in Japan (General Use Survey) with a March 2026 update.
• A significant intangible asset impairment charge linked to ALUNBRIG in Takeda’s FY2026 reporting, reflecting portfolio and commercial reassessment rather than new clinical progress.

“ALUNBRIG Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ALUNBRIG for approved indication like Non-small cell lung cancer ; as well as potential indication like Solid tumours in the 7MM. A detailed picture of ALUNBRIG’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ALUNBRIG for approved and potential indications. The ALUNBRIG market report provides insights about ALUNBRIG’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ALUNBRIG performance, future market assessments inclusive of the ALUNBRIG market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ALUNBRIG sales forecasts, along with factors driving its market.

ALUNBRIG Drug Summary

ALUNBRIG (Brigatinib) is an orally administered, next-generation tyrosine kinase inhibitor developed by Takeda Pharmaceuticals for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It selectively inhibits ALK and has activity against multiple ALK mutations that can contribute to resistance to earlier ALK inhibitors, while also demonstrating penetration into the central nervous system. ALUNBRIG is approved for the treatment of adult patients with metastatic ALK-positive NSCLC and is available as oral tablets, including a once-daily dosing regimen with an initial lead-in period designed to reduce the risk of early pulmonary adverse reactions. Common adverse reactions include nausea, diarrhea, fatigue, cough, headache, hypertension, and increased levels of creatine phosphokinase and liver enzymes, while serious risks include interstitial lung disease/pneumonitis, hypertension, bradycardia, hyperglycemia, and severe muscle toxicity. The report provides ALUNBRIG’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ALUNBRIG Market Report

The report provides insights into:

• A comprehensive product overview including the ALUNBRIG MoA, description, dosage and administration, research and development activities in approved indications like Non-small cell lung cancer ; as well as potential indication like Solid tumours.
• Elaborated details on ALUNBRIG regulatory milestones and other development activities have been provided in ALUNBRIG market report.
• The report also highlights ALUNBRIG‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ALUNBRIG market report also covers the patents information, generic entry and impact on cost cut.
• The ALUNBRIG market report contains current and forecasted ALUNBRIG sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ALUNBRIG market report also features the SWOT analysis with analyst views for ALUNBRIG in approved and potential indications.

Methodology

The ALUNBRIG market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ALUNBRIG Analytical Perspective by DelveInsight

• In-depth ALUNBRIG Market Assessment

This ALUNBRIG sales market forecast report provides a detailed market assessment of ALUNBRIG for approved indication like Non-small cell lung cancer ; as well as potential indication like Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ALUNBRIG sales data uptil 2034.

• ALUNBRIG Clinical Assessment

The ALUNBRIG market report provides the clinical trials information of ALUNBRIG for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ALUNBRIG Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ALUNBRIG Market Potential & Revenue Forecast

• Projected market size for the ALUNBRIG and its key indications
• Estimated ALUNBRIG sales potential (ALUNBRIG peak sales forecasts)
• ALUNBRIG Pricing strategies and reimbursement landscape

ALUNBRIG Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ALUNBRIG Market positioning compared to existing treatments
• ALUNBRIG Strengths & weaknesses relative to competitors

ALUNBRIG Regulatory & Commercial Milestones

• ALUNBRIG Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ALUNBRIG Clinical Differentiation

• ALUNBRIG Efficacy & safety advantages over existing drugs
• ALUNBRIG Unique selling points

ALUNBRIG Market Report Highlights

• In the coming years, the ALUNBRIG market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ALUNBRIG companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ALUNBRIG’s dominance.
• Other emerging products for Non-small cell lung cancer ; as well as potential indication like Solid tumours are expected to give tough market competition to ALUNBRIG and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ALUNBRIG in approved and potential indications.
• Analyse ALUNBRIG cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ALUNBRIG sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ALUNBRIG in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ALUNBRIG? How strong is ALUNBRIG’s clinical and commercial performance?
• What is ALUNBRIG’s clinical trial status in each individual indications such as Non-small cell lung cancer ; as well as potential indication like Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ALUNBRIG Manufacturers?
• What are the key designations that have been granted to ALUNBRIG for approved and potential indications? How are they going to impact ALUNBRIG’s penetration in various geographies?
• What is the current and forecasted ALUNBRIG market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ALUNBRIG in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ALUNBRIG for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ALUNBRIG? What is the duration of therapy and what are the geographical variations in cost per patient?